Esperovax Appoints Robin Robinson as CEO

Esperovax Inc. of Plymouth, an oral RNA vaccine and therapeutic technology company specializing in oral mRNA-based medicines, announced the appointment of Dr. Robin Robinson as president and CEO. Robinson will lead the company from technology, discovery, and early development into the next stages of pre-clinical/ clinical product development and the company’s financial growth.
487
Robin Robinson
Robin Robinson

Esperovax Inc. of Plymouth, an oral RNA vaccine and therapeutic technology company specializing in oral mRNA-based medicines, announced the appointment of Robin Robinson as president and CEO.  Robinson will lead the company from technology, discovery, and early development into the next stages of pre-clinical/ clinical product development and the company’s financial growth.

“Esperovax oral RNA technologies are ripe for further development of selected product candidates in animal and early-stage clinical studies,” says Robinson. “These technologies and supportive data are well-suited to meet vaccine needs for better long-lasting mucosal immunity and to metabolic disease and oncology therapeutic needs for oral RNA drug delivery and gene specific tissue-targeting.”

Robinson is an international scientific and public health leader in novel and innovative vaccines and biothreat medical countermeasures, having served as the vaccine director at Novavax Inc. and the founding director of the Biomedical Advanced Research and Development Authority (BARDA) in the U.S. Government.

Robinson was cited in 2014 – 2016 as one the Top 50 Influential Persons in Vaccines and in 2018 as one of the top 100 innovators in medicine by The Medicine Maker. A pioneer in the creation of Virus=Like Particle (VLP) vaccines, several of his VLP vaccines are licensed vaccines marketed globally. At BARDA using a public-private partnership model, he led hundreds of early-stage product candidates through advanced clinical and manufacturing development resulting in more than 60 FDA-approved and marketed products to date.

Recently Robinson led the development of a novel stem cell therapy to treat wounds from a pre-clinical stage product into clinical studies while serving as the chief scientific officer at RenovaCare, Inc. This effort required his integration of multinational research and development, manufacturing, and clinical site partners with regulatory agencies. These previous and current experiences and skills will serve Esperovax well during its evolving growth.

“The appointment of Dr. Robinson as CEO marks a notable milestone for Esperovax, an organization committed to addressing unmet medical needs and providing hope to patients worldwide, the meaning of “Esperar” in Esperovax,” says Roger Newton, Esperovax board chairman. “Through the development of cutting-edge mRNA-based therapies, the company aims to revolutionize the field of medicine. With Dr. Robinson at the helm, Esperovax is poised